Navigation Links
HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
Date:6/16/2009

apy shows great potential to deliver a compelling, cost-effective option."

The current trial is part of HEALTHPOINT's ongoing development strategy for advancing wound care therapies and further enhances HEALTHPOINT's evidence-based dossier for regulatory filings in both the United States and Europe, according to Mr. Baugh.

About the Study

The study is a randomized, double-blind, dose-finding study involving subjects 18 years of age and older who have had venous leg ulcers for a minimum of six weeks and a maximum of 24 months. The ulcers must be between 2 cm2 and 12 cm2 in area at presentation. The study will assess both the time to complete wound closure and the proportion of complete wound closures in each cohort. It is designed to determine the effectiveness of two cell concentrations and two dosing frequencies of HP802-247 when combined with standard care, compared to placebo plus standard care, in healing venous leg ulcers over a 12-week treatment period. All trial patients undergo compression bandaging with a four-layer system (Profore(R) System) in order to control leg swelling caused by the underlying vein dysfunction.

About HP802-247

HP802-247 consists of two components that are sprayed sequentially on the wound bed at the time of treatment: a fibrinogen solution and a cell preparation containing a mixture of growth arrested, living, allogeneic epidermal keratinocytes and dermal fibroblasts. Based on in vitro studies, HP802-247 is expected to release various growth and angiogenic factors into the microenvironment of the wound through administration of these living, metabolically active, but nonproliferating cells that are trapped on the wound surface in a thin fibrin matrix. The secreted growth and angiogenic factors are anticipated to stimulate the patient's own cells to heal the wound.

About HEALTHPOINT, Ltd.

Since 1992, HEALTHPOINT has
'/>"/>

SOURCE HEALTHPOINT, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
2. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
3. MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series
4. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
5. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
6. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
7. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
8. Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY(TM) Eradicates MRSA From Chronic Venous Ulcers
9. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
10. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
11. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014 UBM Medica US announces ... leading online community and information resource for neurologists and other ... and Alzheimer disease , with discussions of the latest ... 1 million Americans have Parkinson disease , more than the ... Lou Gehrig disease. Diagnosis can be difficult because ...
(Date:10/17/2014)... -- A victim of medical negligence at the hands of ... history of alcohol abuse, a physician and consumer advocates unveiled ... highlighting how Prop 46 will identify and deter physician substance ... The ad pictures a doctor drinking at a bar as ... will enact the first law in the nation requiring random ...
(Date:10/17/2014)... Inc ., reported on results of 59 glaucoma patients treated ... to 3 years with the InnFocus MicroShunt® at the 2014 ... . The Summit was held prior ... American Academy of Ophthalmology . The Company also said it ... countries by early 2015. Logo - http://photos.prnewswire.com/prnh/20141016/152617LOGO ...
Breaking Medicine Technology:Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2
(Date:10/20/2014)... Myoderm announced today the ... their CentralSource service. Matthew will play ... drug sourcing, distribution, and management service for international ... of industry experience, in both business development and ... their international success to help clients manage their ...
(Date:10/20/2014)... Collins, CO (PRWEB) October 20, 2014 ... dGH assays are the only imaging assays capable ... in a single test.  With these three dimensions ... their ability to detect the widest range of ... translocations—mutations usually missed by other genomic tools, including ...
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... his innovative True Form Tummy Tuck® method ... faculty at The University of Texas Medical Branch ... a medical student. Patronella, who is a founding partner ... practices in Texas, The Aesthetic Center for Plastic ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently ... are the best Dedicated Server Hosting suppliers. Their ... to buy high quality hosting and save money ... of Top10BestSEOHosting.com says, “We believe that iPage and ... A lot of the global clients enjoy using ...
Breaking Medicine News(10 mins):Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2
... ,KO Cancer, with Susan G. Komen for the Cure, ... boxers,Felix "Tito" Trinidad and Roy Jones Jr. -- who will ... Jan. 19 -- have teamed with Susan G.,Komen for the ... activists, to help educate and raise awareness regarding the,deadly disease., ...
... diagnostic imaging, BLOOMINGTON, Minn., Dec. 21 ... efficiency of care reduced,medical expenses by $74 million ... introduced in February, reduced unnecessary,tests by more than ... from the American College of Radiology to confirm ...
... BROOK, Ill. December 21, 2007 The ... for the role of endoscopy in treating dyspepsia, discomfort ... a fourth of the population in Western countries. ... instrument to evaluate the inside of the esophagus, stomach ...
... for 2007, CONCORD, Ontario, Dec. 21 ... ,OTG, ,the Company,), a,leading multi- industry computer hardware, ... received an order for 100TB SAN dedicated,to pioneering ... oncology hospitals. The EqualLogic iSCSI SAN order is ...
... HLS ) announced today that its Board of Directors ... on its 6.5%,Series A Convertible Perpetual Preferred Stock, payable ... 2, 2008., About HealthSouth, HealthSouth is the ... states across the country and in,Puerto Rico, HealthSouth serves ...
... by Dr. Steve Bailey, an internationally recognized sports historian, ... the beginnings, achievements and events that shaped the Paralympic ... Movement and other able-bodied sports. , In addition ... First establishes key players in administration and sports politics, ...
Cached Medicine News:Health News:Don King Enlists Prizefighters Felix 'Tito' Trinidad and Roy Jones Jr. to Strike a Blow against Breast Cancer 2Health News:Don King Enlists Prizefighters Felix 'Tito' Trinidad and Roy Jones Jr. to Strike a Blow against Breast Cancer 3Health News:HealthPartners Reports 2007 Most Cost Effective Programs Reduce Expenses by $74 Million 2Health News:ASGE offers guidelines on endoscopic treatment of dyspepsia 2Health News:ASGE offers guidelines on endoscopic treatment of dyspepsia 3Health News:On The Go Ships 100TB Hardware Order for Ground-Breaking Cancer Imaging and Therapy Projects 2Health News:On The Go Ships 100TB Hardware Order for Ground-Breaking Cancer Imaging and Therapy Projects 3Health News:HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock 2Health News:First reputable book on the history of the Paralympic Movement 2
All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Intended for one-time use....
The 100% Silicone construction is ideal for pediatric and latex-sensitive patients....
BARDEX Red Rubber Urethral Catheter (Robinson Model)...
Used for injection into urethral strictures, bladder neck contracture, and the bladder wall. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: